[go: up one dir, main page]

MX2009006454A - Derivados de espiro-piperidina. - Google Patents

Derivados de espiro-piperidina.

Info

Publication number
MX2009006454A
MX2009006454A MX2009006454A MX2009006454A MX2009006454A MX 2009006454 A MX2009006454 A MX 2009006454A MX 2009006454 A MX2009006454 A MX 2009006454A MX 2009006454 A MX2009006454 A MX 2009006454A MX 2009006454 A MX2009006454 A MX 2009006454A
Authority
MX
Mexico
Prior art keywords
sup
piperidine derivatives
spiro
present
compounds
Prior art date
Application number
MX2009006454A
Other languages
English (en)
Inventor
Mark Rogers-Evans
Raffaello Masciadri
Patrick Schnider
Hasane Ratni
Caterina Bissantz
Christophe Grundschober
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2009006454A publication Critical patent/MX2009006454A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a nuevos derivados de espiro-piperidina como antagonistas del receptor de V1a, su manufactura, composiciones farmacéuticas que los contienen y su utilización como medicamentos. Los compuestos activos de la presente invención son útiles en la prevención y/o tratamiento de ansiedad, trastornos depresivos y otras enfermedades. Los compuestos de la presente invención se describen con la fórmula general (I), en donde R1 a R5, R5,, R7 a R9, R7,, R8,, X y Y son como se definen en la especificación.
MX2009006454A 2006-12-22 2007-12-13 Derivados de espiro-piperidina. MX2009006454A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06127086 2006-12-22
PCT/EP2007/063879 WO2008077810A2 (en) 2006-12-22 2007-12-13 Spiro-piperidine derivatives

Publications (1)

Publication Number Publication Date
MX2009006454A true MX2009006454A (es) 2009-06-26

Family

ID=39209551

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006454A MX2009006454A (es) 2006-12-22 2007-12-13 Derivados de espiro-piperidina.

Country Status (16)

Country Link
US (3) US20080153863A1 (es)
EP (2) EP2097376A2 (es)
JP (1) JP2010513384A (es)
KR (1) KR20090082502A (es)
CN (1) CN101563324A (es)
AR (1) AR064481A1 (es)
AU (1) AU2007338115A1 (es)
BR (1) BRPI0721138A2 (es)
CA (1) CA2673307A1 (es)
CL (1) CL2007003720A1 (es)
MX (1) MX2009006454A (es)
NO (1) NO20092149L (es)
PE (1) PE20081833A1 (es)
RU (1) RU2009123133A (es)
TW (1) TW200833697A (es)
WO (1) WO2008077810A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2102207B1 (en) * 2006-12-07 2010-06-02 F.Hoffmann-La Roche Ag Spiro-piperidine derivatives as via receptor antagonists
US20080153863A1 (en) * 2006-12-22 2008-06-26 Caterina Bissantz Spiropiperidine derivatives
KR20120104512A (ko) 2009-07-14 2012-09-21 알바니 몰레큘라 리써치, 인크. 5-ｈｔ3 수용체 조절체, 이의 제조 방법, 및 그의 용도
BR112015000443A2 (pt) 2012-07-10 2017-06-27 Bayer Pharma AG derivados de estra-1,3,5(10),16-tetraeno 3-substituídos, processo para a sua produção, preparações farmacêuticas que contêm os mesmos, bem como seu uso para a produção de medicamentos
PE20151754A1 (es) 2013-02-21 2015-12-20 Bayer Pharma AG Estra-1,3,5(10),16-tetraeno-3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
MX2021007152A (es) 2018-12-17 2021-11-03 Vertex Pharma Inhibidores de apol1 y sus metodos de uso.
MX2023002269A (es) 2020-08-26 2023-05-16 Vertex Pharma Inhibidores de apol1 y metodos para usar los mismos.
JP2025505645A (ja) * 2022-02-08 2025-02-28 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｐｏｌ１の阻害剤としてのスピロピペリジン誘導体およびその使用方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3370091A (en) * 1964-06-15 1968-02-20 Hoffmann La Roche 2 aminobenzhydrylhalides
US3531467A (en) * 1966-12-23 1970-09-29 Hoffmann La Roche Process for the preparation of 2,3,4,5-tetrahydro - 5 - aryl - 1h - 1,4 - benzodiazepine derivatives
US4209625A (en) * 1977-04-21 1980-06-24 American Hoechst Corporation Spiro[indoline-3,4'-piperidine]s
DE3818830A1 (de) * 1988-06-03 1989-12-14 Boehringer Mannheim Gmbh Bicyclische carboxamide, verfahren zu ihrer herstellung, deren vorstufen, und diese verbindungen enthaltende arzneimittel
DK78692D0 (da) 1992-06-12 1992-06-12 Lundbeck & Co As H Dimere piperidin- og piperazinderivater
EP0663827A4 (en) * 1992-10-07 1995-11-15 Merck & Co Inc TOKOLYTIC OXYTOCINE RECEPTOR ANTAGONISTS.
US5670509A (en) * 1993-09-27 1997-09-23 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
IT1271026B (it) 1994-10-21 1997-05-26 Isagro Ricerca Srl Derivati dell'acido b-amminopropionico ad attivita' fungicida
US5576321A (en) 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
EA000992B1 (ru) * 1995-12-14 2000-08-28 Мерк Энд Ко., Инк. Антагонисты гормона, высвобождающего гонадотропин
GB9601724D0 (en) * 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US6166209A (en) 1997-12-11 2000-12-26 Hoffmann-La Roche Inc. Piperidine derivatives
CO5150201A1 (es) 1998-09-07 2002-04-29 Hoffmann La Roche Derivados de piperidina
JP2002528499A (ja) 1998-10-29 2002-09-03 ブリストル−マイヤーズ スクイブ カンパニー Ｉｍｐｄｈ酵素のインヒビターであるアミノ核誘導化合物
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
TWI279402B (en) * 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
GB0003397D0 (en) * 2000-02-14 2000-04-05 Merck Sharp & Dohme Therapeutic agents
ATE255578T1 (de) 2000-05-12 2003-12-15 Solvay Pharm Bv Piperazin- und piperidinverbindungen
ES2220811T3 (es) 2000-09-29 2004-12-16 Eli Lilly And Company Procedimiento y compuestos para el tratamiento de enfermedades proliferativas.
WO2003040141A1 (en) 2001-09-28 2003-05-15 Bayer Pharmaceuticals Corporation Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders
WO2003045385A1 (en) 2001-11-27 2003-06-05 F. Hoffmann-La Roche Ag Benzothiazole derivatives
FR2833948B1 (fr) * 2001-12-21 2004-02-06 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et leur utilisation en tant que medicament
WO2003095448A1 (en) 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
US20040152741A1 (en) 2002-09-09 2004-08-05 Nps Allelix Corporation Arylglycine derivatives and their use as glycine transport inhibitors
AU2003263155A1 (en) 2002-09-20 2004-04-08 H. Lundbeck A/S Method for manufacture of dihydroisobenzofuran derivatives
US7582761B2 (en) 2002-10-17 2009-09-01 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2004069809A1 (en) 2003-02-03 2004-08-19 Janssen Pharmaceutica N.V. Mercaptoimidazoles as ccr2 receptor antagonists
US7244852B2 (en) * 2003-02-27 2007-07-17 Abbott Laboratories Process for preparing 2-methylpyrrolidine and specific enantiomers thereof
AU2004225977B2 (en) 2003-03-25 2011-03-24 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
EP1615698B1 (en) 2003-04-11 2010-09-29 High Point Pharmaceuticals, LLC New amide derivatives and pharmaceutical use thereof
DK1663242T3 (da) 2003-08-07 2011-08-01 Rigel Pharmaceuticals Inc 2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler
CA2544602A1 (en) 2003-11-04 2005-05-26 Elixir Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
JP2007516298A (ja) * 2003-12-23 2007-06-21 アリーナ ファーマシューティカルズ， インコーポレイテッド 新規なスピロインドリンまたはスピロイソキノリン化合物、それらの使用方法および組成物
MX2007001431A (es) 2004-08-05 2007-04-02 Hoffmann La Roche Derivados de indol, de indazol o de indolina.
WO2006040329A1 (en) 2004-10-12 2006-04-20 Novo Nordisk A/S 1 ibeta- hydroxysteroid dehydrogenase type 1 active spiro compounds
WO2006123242A1 (en) * 2005-05-18 2006-11-23 Pfizer Limited 1, 2, 4 -triazole derivatives as vasopressin antagonists
US8190027B2 (en) * 2006-07-12 2012-05-29 Tellabs Operations, Inc. Multifunctional and reconfigurable optical node and optical network
PL1904477T3 (pl) * 2005-07-14 2009-07-31 Hoffmann La Roche Pochodne indolo-3-karbonylo-spiro-piperydyny jako antagoniści receptora V1a
JP2009507800A (ja) 2005-09-09 2009-02-26 ユーロ−セルティーク エス．エイ． 縮合およびスピロ環化合物ならびにその使用
MY167260A (en) 2005-11-01 2018-08-14 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
AU2007252643A1 (en) 2006-05-19 2007-11-29 Eisai R & D Management Co., Ltd. Urea type cinnamide derivative
EP2046828A2 (en) 2006-07-07 2009-04-15 Wyeth Nogo receptor functional motifs, peptide mimetics, and mutated functional motifs related thereto, and methods of using the same
EP2102207B1 (en) 2006-12-07 2010-06-02 F.Hoffmann-La Roche Ag Spiro-piperidine derivatives as via receptor antagonists
US20080153863A1 (en) * 2006-12-22 2008-06-26 Caterina Bissantz Spiropiperidine derivatives
ES2351949T3 (es) * 2006-12-29 2011-02-14 F. Hoffmann-La Roche Ag Derivados de azaspiro.
CN101583615B (zh) * 2007-01-12 2012-07-04 弗·哈夫曼-拉罗切有限公司 螺哌啶甘氨酰胺衍生物
MX2009012163A (es) 2007-05-11 2009-12-01 Hoffmann La Roche Hetarilanilinas como moduladores para beta-amiloide.
ES2535166T3 (es) 2007-09-04 2015-05-06 The Scripps Research Institute Pirimidinil-aminas sustituidas como inhibidores de proteína-quinasas

Also Published As

Publication number Publication date
EP2097376A2 (en) 2009-09-09
CL2007003720A1 (es) 2008-07-11
CN101563324A (zh) 2009-10-21
KR20090082502A (ko) 2009-07-30
CA2673307A1 (en) 2008-07-03
AU2007338115A1 (en) 2008-07-03
WO2008077810A2 (en) 2008-07-03
WO2008077810A3 (en) 2008-09-25
EP2535329A3 (en) 2013-03-27
BRPI0721138A2 (pt) 2014-04-01
JP2010513384A (ja) 2010-04-30
RU2009123133A (ru) 2011-01-27
EP2535329A2 (en) 2012-12-19
PE20081833A1 (es) 2008-12-27
NO20092149L (no) 2009-06-18
US20080153862A1 (en) 2008-06-26
US20080153863A1 (en) 2008-06-26
TW200833697A (en) 2008-08-16
AR064481A1 (es) 2009-04-01
US20080153861A1 (en) 2008-06-26
US8084609B2 (en) 2011-12-27

Similar Documents

Publication Publication Date Title
WO2008080844A9 (en) Azaspiro derivatives
MX2009007411A (es) Derivados de espiropiperidina-glicinamida.
MX2009005507A (es) Derivados de espiro-piperidina.
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
MX2009006454A (es) Derivados de espiro-piperidina.
MX2009006540A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides.
MX2010004026A (es) Piperidino-dihidrotienopirimidinas sustituidas.
MY147588A (en) (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives
MX2010005861A (es) Agonistas novedosos de los receptores de glucocorticoides.
BR0315547A (pt) Derivados de quinolina como antagonistas de crth2
GB0625648D0 (en) Compounds
PT1716152E (pt) Compostos heterocíclicos fundidos e sua utilização como antagonistas do receptor metabotrópico para o tratamento de distúrbios gastrointestinais
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MX2009005544A (es) Indoles.
MX2009006010A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenoreceptor beta 2.
MX2009005541A (es) Indoles que actuan como antagonistas del receptor v1a.
DK1725536T3 (da) Imidazolin-derivater med CB1-antagonistisk aktivitet
TW200736189A (en) Indene derivatives, their preparation and use as medicaments
MX2009006446A (es) Derivados de espiro-piperidina.
MX2009005504A (es) Derivados de espiro piperidina como antagonistas del receptor via.
TW200731975A (en) Novel combinations of medicaments for the treatment of respiratory diseases
TW200640465A (en) New pharmaceutically active compounds for the treatment of respiratory diseases
MX2009006920A (es) Indoles.
MX2009010729A (es) Derivados de dihidro-benzo[b] [1,4]diazepin-2-ona-sulfonamida.

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal